Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02740114 · ClinicalTrials.gov registry record · Phase 3

Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway

A Phase 3 study, sponsored by M.D. Anderson Cancer Center.

Terminated
Registry status
Phase 3
Development phase
105
Enrollment target

NCT02740114: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.

NCT02740114 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 105 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02740114, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.

TERMINATED
Registry status
Phase 3
Development phase
105 participants
Enrollment target

Study Summary

Bupivacaine is a drug that is traditionally given as an injection to numb surgical sites. Liposomes are molecules that are similar to fats. Sometimes drugs are combined with liposomes to make them able to stay in the body for longer periods of time. This has been done with bupivacaine to create liposomal bupivacaine. The goal of this clinical research study is to compare the effects of bupivacaine to those of liposomal bupivacaine when given to patients who are having gynecologic surgery. Researchers want to compare how long the drugs work to numb the wound and how long patients take to recover from surgery.

Primary Outcome

Treatment arms compared with respect to the proportion of patients opioid-free at 48 hours using the Cochran-Mantel-Haenszel test stratified by surgeon.

Interventions

  • DRUG Bupivacaine
  • DRUG Liposomal Bupivacaine
  • DRUG Oxycodone
  • BEHAVIORAL Symptom Questionnaire
  • BEHAVIORAL Pill Diary

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2016-08-31
Est. Completion 2020-07-23
Phase Phase 3
M.D. Anderson Cancer Center

2,692 total trials

Why NCT02740114 stopped before completion

NCT02740114 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (86% lower).

The record links to 0 conditions, and to 5 interventions - of which Bupivacaine is the first listed.

NCT02740114 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02740114 about?

NCT02740114 is a clinical study titled "Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway". Bupivacaine is a drug that is traditionally given as an injection to numb surgical sites. Liposomes are molecules that are similar to fats. Sometimes drugs are combined with liposomes to make them able to stay in the body for longer periods of time. This has been done with bupivacaine to create lipo...

What is the current status of trial NCT02740114?

This trial is currently terminated. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 2016-08-31. Estimated completion is 2020-07-23.

What interventions are being tested in trial NCT02740114?

The interventions under investigation include: Bupivacaine (DRUG), Liposomal Bupivacaine (DRUG), Oxycodone (DRUG), Symptom Questionnaire (BEHAVIORAL), Pill Diary (BEHAVIORAL).

Who is sponsoring clinical trial NCT02740114?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02740114's enrollment target sits among peer trials

105 1670th of 2000 higher than 330 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03372317 · 105 participants

    Tau PET in Imaging and Cognition: Healthy Adults From 55-90

  • NCT04253964 · 105 participants · Phase 2

    Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

  • NCT04742452 · 105 participants · NA

    Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears

  • NCT04875429 · 105 participants · NA

    Zenith® Fenestrated+ Clinical Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02740114, the US trial registry maintained by the National Library of Medicine. NCT02740114 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.